#Ireland #Dublin #Peyronie's Disease #XIAFLEX #Keenova

Keenova's Presentation Highlights at the SMSNA Annual Meeting

Keenova Therapeutics plc has announced an engaging agenda for the upcoming Sexual Medicine Society of North America (SMSNA) annual meeting, scheduled for October 8-11, 2026. The company is set to share valuable data and insights on various men's health issues, prominently focusing on treatment options for Peyronie's disease. This condition, which can severely affect a man's sexual health, involves a painful curvature of the penis caused by fibrous scar tissue, impacting both virtual and intimate experiences.

Key Presentations

Keenova's lineup includes three pivotal presentations:
1. Collagenase Clostridium Histolyticum for Ventral Curvature due to Peyronie's Disease: This talk will present findings from a multicenter retrospective Phase 4 observational study, emphasizing the role of XIAFLEX® in treating men experiencing ventral curvature associated with this condition.

2. Real-World and Phase 4 Outcomes: The second presentation will dive into a literature review addressing the real-world application and effectiveness of XIAFLEX, detailing actual treatment outcomes.

3. Men’s Sexual Health Screener: This session introduces a new clinician-patient communication tool designed to efficiently discuss and assess sexual health concerns in healthcare environments, fostering better dialogue and understanding between healthcare providers and their patients.

Dr. Jesse Mills, a key figure at UCLA Health, expressed enthusiasm about sharing these findings, which highlight the importance of effective treatment options and resources tailored to men’s sexual health. He noted that such initiatives are essential for encouraging open discussions regarding sexual health issues among men, ultimately aiding in informed treatment decisions.

Understanding Peyronie’s Disease

Peyronie’s disease affects approximately 1 in 10 men, yet many remain undiagnosed due to the stigma and discomfort surrounding the topic. The condition can exacerbate feelings of anxiety and embarrassment, making it vital for healthcare providers to approach the topic with sensitivity and understanding. Dr. Mills pointed out that this condition's treatment options can significantly enhance men's health and quality of life, making educational outreach and conversation a priority.

About XIAFLEX and Its Indications

XIAFLEX® is approved for adult men with Peyronie’s disease presenting a palpable plaque and curvature deformity of at least 30 degrees. It’s crucial for practitioners to be aware of the risks associated with its use, including severe adverse reactions like corporal rupture and the occurrence of penile hematomas, which have been documented in clinical studies.

Keenova is committed to ensuring patient safety and is working within a Risk Evaluation and Mitigation Strategy (REMS) program to manage these risks effectively, allowing healthcare professionals access to potentially life-changing treatment options while prioritizing patient safety.

Conclusion

Keenova's presence at the SMSNA annual meeting signifies a crucial step toward advancing men’s sexual health and improving treatment accessibility. By offering innovative solutions and fostering communication through educational tools, the company aims to empower men to address their sexual health concerns effectively. For more on Keenova's upcoming presentations and broader mission in men’s health, visit Keenova's official website.

We can look forward to further developments in treatment options, supporting men in their health journeys as Keenova shares its findings with the medical community.